KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first antibody discovery and design, announced a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (“IFX-101”) program.

The first antibody in Infinimmune’s therapeutic drug development pipeline, IFX-101, targets atopic dermatitis and is designed to deliver superior efficacy with extended dosing intervals for improved patient quality of life. By sourcing antibodies directly from the human immune system, Infinimmune taps into a naturally optimized, safe, and effective therapeutic reservoir, rather than engineering from scratch. Infinimmune’s GLIMPSE™ platform – a protein language model trained solely on native human antibody sequences – learns from millions of successful immune responses to engineer superior antibodies that harness evolution-proven strategies with enhanced biologic properties. This combination creates a potent platform that’s uniquely differentiated in the biologics field.

“We are pleased to partner with KBI Biopharma to advance our lead antibody program,” said Wyatt McDonnell, Ph.D., CEO and Co-Founder, Infinimmune. “By combining our Anthrobody® and GLIMPSE™ platforms together with KBI’s development and manufacturing expertise, we’re positioned to rapidly advance toward clinical trials. Our human-first approach enables us to deliver what patients really need – more effective treatments with greater convenience. This collaboration is an important step in our mission to bring transformative, human-first antibodies to patients in need."

“KBI is proud to support Infinimmune in its effort to transform biologics and deliver safer, more effective antibody therapeutics,” said Katie Edgar, Chief Business Officer of KBI Biopharma. “Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune’s cutting-edge antibody discovery with KBI’s deep expertise in development and manufacturing capabilities.”

The IFX-101 program is progressing at KBI’s Cell Line Development Center of Excellence in Geneva, Switzerland, using KBI’s advanced monoclonal antibody development and manufacturing platform, SUREmAb™, powered by Selexis.